TY  -  
T1  - Novel personalized cancer vaccine platform based on Bacillus Calmette-Guerin 
SN  -  /  
UR  - http://hdl.handle.net/10138/334461 
T3  -  
A1  - Ylösmäki, Erkko; Fusciello, Manlio; Martins, Beatriz; Feola, Sara; Hamdan, Firas; Chiaro, Jacopo; Ylösmäki, Leena; Vaughan, Matthew J.; Viitala, Tapani; Kulkarni, Prasad S.; Cerullo, Vincenzo 
A2  -  
PB  -  
Y1  - 2021 
LA  - eng 
AB  - Background Intratumoral BCG therapy, one of the earliest immunotherapies, can lead to infiltration of immune cells into a treated tumor. However, an increase in the number of BCG-induced tumor-specific T cells in the tumor microenvironment could lead to enhanced therapeutic effects. Methods Here, we have developed a novel cancer vaccine platform based on BCG that can broaden BCG-induced immune responses to include tumor antigens. By physically attaching tumor-specific peptides onto the mycobacte... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - adaptive immunity; immunity; cellular; immunogenicity; vaccine; immunotherapy; active; ADVANCED MELANOMA PATIENTS; MYCOBACTERIUM-BOVIS BCG; PRIME-BOOST VACCINATION; TOPICAL IMIQUIMOD; IMMUNE-RESPONSES; SURFACE-CHARGE; B16 MELANOMA; TUMOR-GROWTH; VIRUS; IMMUNOTHERAPY; 3122 Cancers; 317 Pharmacy 
N1  -   
PP  -  
ER  -